Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison
Bioengineering · 09.07.2026 · 13 (7) · 789
DOI: 10.3390/bioengineering13070789 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering, online erschienen am 09.07.2026. Verfasst von Jeong-Gyu Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hallym University.
Abstract (Originalsprache)
Background
Mirikizumab, a first-in-class interleukin-23p19 antagonist, was approved for ulcerative colitis (2023) and Crohn’s disease (2025). The US Food and Drug Administration (FDA) identified a hepatotoxicity signal during pre-approval review, mandating post-marketing surveillance. No independent pharmacovigilance analysis has been published.
Aims
To characterise the post-marketing safety profile of mirikizumab using multi-database pharmacovigilance, with a focus on hepatotoxicity and IL-23 inhibitor class comparison.
Methods
Disproportionality analysis of the FDA Adverse Event Reporting System (FAERS; Q4 2023–Q4 2025) and Japanese Adverse Drug Event Report database (JADER) was performed using four algorithms (reporting odds ratio, proportional reporting ratio, Bayesian confidence propagation neural network, empirical Bayesian geometric mean). Signals of disproportionate reporting were defined by concordance of all four methods. Active comparator analysis against risankizumab, guselkumab and ustekinumab, Weibull time-to-onset modelling and hepatotoxicity case characterisation were conducted. Reporting followed READUS-PV guidelines.
Results
We identified 564 mirikizumab reports in FAERS and 123 in JADER. Nine signals met all four criteria in FAERS, including spontaneous abortion (Reporting odds ratio (ROR) 10.16, 95% CI 5.16–20.02), pulmonary embolism (ROR 5.56, 2.93–10.56) and injection site reactions. Hepatotoxicity showed no disproportionate reporting in either FAERS (ROR 1.19, 0.74–1.92; n = 17) or JADER (ROR 0.24, 0.05–1.19; n = 1). Comparator analysis identified cytomegalovirus infection and interstitial lung disease as mirikizumab-specific versus the IL-23 class. Weibull analysis (β = 0.65) indicated early-onset adverse event clustering.
Discussion
This first multi-database pharmacovigilance study of mirikizumab did not confirm the FDA-flagged hepatotoxicity signal. Potential signals warranting further investigation include thromboembolic events and pulmonary toxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of New Frontier Research, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea.
- Department of Internal Medicine, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, Hallym University College of Medicine, Chuncheon 24253, Republic of Korea.
ORCID-Profile: Eun Jeong Gong, Chang Seok Bang
Förderung
- Hallym University
Zitieren
APA
Choi, J. G., Gong, E. J., Bang, C. S., & Lee, J. J. (2026). Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison. Bioengineering, 13(7), 789. https://doi.org/10.3390/bioengineering13070789
Vancouver
Choi JG, Gong EJ, Bang CS, Lee JJ. Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison. Bioengineering. 2026;13(7):789. doi:10.3390/bioengineering13070789
BibTeX
@article{Choi2026,
author = {Choi, Jeong-Gyu and Gong, Eun Jeong and Bang, Chang Seok and Lee, Jae Jun},
title = {Post-Marketing Safety Profile of Mirikizumab: A Multi-Database Pharmacovigilance Study Using FAERS and JADER with IL-23 Inhibitor Class Comparison},
journal = {Bioengineering},
year = {2026},
volume = {13},
number = {7},
pages = {789},
doi = {10.3390/bioengineering13070789}
}
EUVIMED